Sold as Saluron. Every FDA application for this active ingredient: 1 branded and 4 generic.
As of Nov 15, 2026, FDA lists 5 applications for Hydroflumethiazide (sold as Saluron), first approved Jul 22, 1959, with 0 new uses approved and 0 published complete response letters.
| Jul 22, 1959 | SaluronNDA 11949 · New molecular entity | Shire LLC | 17 | Discontinued |
| Dec 20, 1973 | DiucardinANDA 83383 | Wyeth Ayerst | 5 | Discontinued |
| May 31, 1985 | HydroflumethiazideANDA 88850 | Par Pharm | 5 | Discontinued |
| — | HydroflumethiazideANDA 88031 | Watson Labs | 3 | Discontinued |
| — | HydroflumethiazideANDA 88528 | Watson Labs | 1 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Par Pharm